Schering Noxafil Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering-Plough's triazole antifungal Noxafil (posaconazole oral suspension) shows significantly better results than standard antifungals in a study presented Dec. 8 at the American Society of Hematology meeting. Overall success rate was 42% in patients receiving Noxafil 800 mg/day for up to one year, vs. 26% for standard therapy (p=0.006). Noxafil is one of three launches Schering is anticipating by 2007; the firm also expects to introduce the oncologic Sarasar (lonafarnib) and a fixed combination of Zetia and Zocor, which is pending at FDA with a July user fee goal...
You may also be interested in...
Schering-Plough submits Noxafil NDA
Schering-Plough's triazole antifungal Noxafil (posaconazole) has a user fee date of March 2005 under a standard review clock, the company announces July 13. The May NDA covers treatment of invasive fungal infections refractory to or intolerant of existing therapies. Phase III results presented at the American Society of Hematology meeting in December 2003 showed an overall success rate of 42% for Noxafil vs. 26% for standard therapy (1Pharmaceutical Approvals Monthly Dec. 1, 2003, In Brief)...
Schering Ends Sarasar Lung Cancer Trial, Leaving One Novel Agent In Phase III
Schering-Plough is discontinuing its Sarasar Phase III program in non-small cell lung cancer after an interim analysis suggested the data will not demonstrate efficacy.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.